Business
US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second program IND has been submitted to US FDA for clinical trial targeting MYC-aberrant lymphoma. Following the initiation of the first trial using CX-5461 as a monotherapy in advanced solid tumors, the IND-submission of the second trial marks a milestone in t
About this update from Senhwa Biosciences Inc
[{"type":"text","content":"TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second program IND has been submitted to US FDA for clinical trial targeting MYC-aberrant lymphoma. Following the initiation of the first trial using CX-5461 as a monotherapy in advanced solid tumors, the IND-submission of the second trial marks a milestone in the development of CX-5461.","length":581,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Senhwa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Senhwa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":213,"height":54,"url":"https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hyBQWbX_FTtRFjftnr2Otg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b","width":213,"height":54}},"href":"https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"With sponsorship from the NCI, this program significantly reduces Senhwa's clinical development expenditures, easing its R&D financial demands while enhancing the overall project value and commercialization potential—a major positive for the company's future growth.","length":278,"tagName":"p"},{"type":"text","content":"A Globally Innovative G4-Targeting Mechanism Against Hard-to-Treat MYC-Driven Lymphomas – 30% of Cancers Involve MYC Mutation","length":125,"tagName":"p"},{"type":"text","content":"MYC is a critical oncogene, with approximately 28% of cancer patients exhibiting gene amplification or mutation, including in lung, breast, liver cancers, and lymphomas. The MYC protein drives cell proliferation, angiogenesis, and apoptosis suppression, playing a key role in multiple malignancies. CX-5461, developed by Senhwa, precisely stabilizes the G-quadruplex (G4) structures in DNA within cancer cells, suppressing MYC gene expression and effectively disrupting tumor growth pathways.","length":492,"tagName":"p"},{"type":"text","content":"Preclinical...